Lukmed 2 Sp. z o.o.

Siedlce 39 trials 16 recruiting

39 Registered trials

16 Currently recruiting

Organisation

Lukmed 2 Sp. z o.o.

Location

Siedlce, Poland

Identifier

ORG-100040573

Address

Ul. Mlynarska 16 B, 08-110, Poland

Departments

205-ETG Siedlce
616012: ETG Siedlce
Chronic pain
ETG Siedlce
Lukmed 2 Sp
Lukmed 2 Sp. z o.o. ETG Siedlce
N/A
NA
Private Practice
Site name: ETG Siedlce

Clinical trials at this site (39)

Search interface

A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in… Ended

2024-510826-16-00 Rheumatoid Arthritis 5 2025-04-07
Once-weekly petrelintide versus placebo for obesity or overweight with comorbidities Ended

2024-512549-18-00 Weight management 4 2024-12-19
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510339-12-00 acne vulgaris 5 2024-11-11
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended

2023-506664-14-00 Rheumatoid Arthritis 5 2024-10-24
A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended

2023-509412-28-00 Type 2 Diabetes 4 2024-07-26
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended

2022-501310-57-00 Endometriosis related pain 4 2024-02-05
A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended

2022-502529-17-00 Obesity 5 2024-01-18
A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended

2022-502531-18-00 Obesity 5 2024-01-18
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended

2023-503790-37-00 Post-Menopausal Osteoporosis 5 2024-01-09
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12